engleski

Imiquimod

Since its first official approval for use in external genital and perianal warts about 16 years ago, imiquimod has revolutionized not only the therapeutic protocols but also our understanding of the immunogenetic properties of some of the most frequent dermatovenereological disorders. Besides the aforementioned external genital and perianal warts, imiquimod 5 % cream is officially approved for treatment of superficial small (<2 cm) non-facial basal cell carcinoma (BCC) and actinic keratoses on the face and scalp. However, the list of off-label indications continues to expand offering potential cost-effective and more elegant treatment options. The most relevant updates about the use of imiquimod in dermatology and venereology have been briefly summarized in this chapter.

Imiquimod, indication for use in dermatovenereology

nije evidentirano